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Abstract
Investigating the Role of CD109 in Pancreatic Ductal Adenocarcinoma
MennatAllah Shaheen, M.S.
Advisory Professor: Giulio F. Draetta, M.D., Ph.D.

Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in
the US. We performed loss of function genomic screening on a cohort of four patient
derived PDAC cell populations and our data shows a cell surface receptor CD109 to be
a common vulnerability, the biologic role of which in PDAC is yet unstudied and largely
unknown. We hypothesized that CD109 expression provides PDAC cells with a survival
advantage, and promotes cancer progression through activation of downstream
signaling. We believe therefore that targeting CD109 could improve PDAC patients’
survival. Here we report that CD109 plays a role in cell proliferation, viability, and
clonogenicity in vitro. We also find that it promotes tumor formation and progression in
nude mice, therefore decreasing their survival. We revealed an association between
CD109 expression and YAP/TAZ signaling through RPPA and RNA Sequencing data.
This data establishes CD109 as a cell surface protein exclusively expressed in PDAC
rather than healthy pancreatic tissue, demonstrating pro-oncogenic behavior and tumor
initiation potential in vitro and in vivo. This helps us understand more about PDAC and
provides insights into a relatively unknown protein with a therapeutic potential.
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1. Introduction:
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common type of
pancreatic cancer (90%) and the fourth leading cause of cancer related deaths in the
world[1]. The most effective therapeutic approach is surgical resection; however, most
patients are diagnosed with late-stage, unresectable disease. PDACs are highly
recalcitrant tumors that respond poorly to standard-of-care chemotherapeutic regimens,
and little progress has been made with the addition of targeted agents or
immunotherapies, resulting in a 5-year survival rate of only 8% [2]. At least 90% of
PDACs are driven by mutant KRAS, which has made quenching the downstream
effector proteins of this oncogene an attractive therapeutic target [3]. Unfortunately, to
date, these approaches have been unsuccessful in the clinic, and there is an urgent
need to identify new therapeutic targets that may disrupt cancer-essential, KRAS-driven
functions in PDAC [4].
1.1 Loss of Function Genomic Screening
Our laboratory conducted loss of function (LOF) genomic screens in four early passage
PDAC models derived from patients at MD Anderson in both in vivo and in vitro settings.
The purpose of these loss-of-function RNAi screens was to functionally inform on a set
of PDAC-prioritized genes located at the extracellular face of the plasma membrane
(the cell “surfaceome”). The screens were performed using a pooled barcoded lentiviral
library on cell lines generated from patient-derived xenografts (PDXs). Timing and
library coverage conditions were optimized. PDX models were established prior to
screening, and were chosen to cover the molecular spectrum of PDAC from Classical to
Basal-like subtypes and were based on empty barcode library assays, i.e. barcode-only
1

libraries of the same size. A platform was optimized for two-step PCR-based barcode
isolation for both in vitro and orthotopic in vivo screening. Functional targets were
defined in the context of paired 2D and orthotopic in vivo conditions over at least two
time points. The last time point (28 days) was used for the target described. This
provides a look into how surface associated targets differ across the PDAC spectrum,
and also which targets seem to be persistent. Targets that are persistent and unstudied,
in the context of PDAC, provide a straightforward avenue to leverage for vulnerability
and mechanistic insight. Redundant siRNA Analysis (RSA) which is a score based on
fold change depletion relative to the reference barcode population, was used to
calculate hit priority. The quality of the data is based on control separation, library
coverage and biological replicate reproducibility. CD109 is one of the few targets that
scored across all the models in the RNAi screens.
1.2 CD109: A History
In 1991 in an experiment to discover new antigens on the surface of primitive
hematopoietic stem cells, CD109 was first recognized by monoclonal antibodies as a
170 KD glycoprotein expressed in CD34+ acute myeloid leukemia cell line, KG1a. In
that study, CD109 was reported to mark a more primitive hematopoietic stem cell
subset, its expression becoming more limited as these cells differentiate, eventually
becoming undetectable in mature resting blood cells, and only expressed in a restricted
pattern on the surface of activated platelets, activated T-lymphocytes and endothelial
cells[5]. After that CD109 role in blood cells became an interesting question. Studies
related CD109 to the α2 – macroglobulin/ complement family of thioester proteins and
showed that it carries the human platelet antigen 15 (HPA-15 or Gov-a/b) which is
2

implicated in neonatal alloimmune thrombocytopenia (NAT), and post-transfusion
purpura, but beyond that its physiological action in blood remained unclear[6-10].
1.3 CD109: Structure
CD109 protein consists of 1445 aa. It has a leader signaling peptide on the N-terminal,
a GPI-anchor on the C-terminal as well as a thioester and a furinase cleavage sites
(figure1.1(a)). After translation, CD109 protein enters the endoplasmic reticulum for
posttranslational

modifications

where

it

gets

glycosylated

and

linked

to

glycosylphosphatidylinositol (GPI). Then CD109 is cleaved at the furinase site into two
fragments in the golgi apparatus, and exported together to the cell surface as a
complex, where it can also detach and be secreted in the medium (figure1.1 (b)).[11]
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(a)

(b)

Figure 1.1 CD109 Structure and Posttranslational Journey
(a) Diagrammatic representation of CD109 protein.
(b) Sequence of events from CD109 RNA translation to surface expression and
extracellular secretion. (Hagiwara et al. 2010)
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1.4 CD109 in Physiological Conditions
CD109 expression in normal tissues seems to be restricted to: myoepithelial cells of the
mammary, lacrimal, salivary, and bronchial glands, bronchial epithelia and epidermis,
seminiferous tubules of the testis, basal cells of the prostate, and osteoblasts and
osteoclasts. Yet its function in each organ or tissue is not clear [12-14]. One study
attempted a CD109 knockout mouse model (CD109-/-) and they found the mice to be
viable but with abnormal skin and hair growth. The group later re-analyzed these mice
by investigating their bones after reports of CD109 expression on pre-osteoclasts and
its role in osteoclast formation in vitro. Indeed, they found that CD109 deficient mice
have significantly less bone volume and more bone turnover compared to wild type
mice, resulting in an osteoporosis-like effect. Both studies imply that CD109 might have
a role in keratinocyte differentiation and normal bone turn over in humans[13, 14].
1.5 CD109 in Cancer
Much earlier than the CD109-/- mouse studies, reports on CD109 overexpression in
cancer were published. CD109 is involved in glioma, glioblastoma, lung and breast
cancer

where

it

associates

with

a

more

mesenchymal

form

of

disease,

chemoresistance, poor prognosis and seems to factor in tumor initiation. CD109
overexpression is also detected in various sarcomas, and squamous cell carcinomas
including the uterus, and esophagus, hepatocellular carcinoma, bladder urothelial
carcinoma, and lately, pancreatic adenocarcinoma joins the list. A study using
glycoprotein surface capture technique detected significant difference between CD109
expression in PDAC and in normal pancreas (figure1.2)[15]. Another study aimed at
5

developing specific monoclonal antibody against CD109 and the antibody could detect
CD109 in 96% of their cohort of 65 PDAC samples[16]. CD109 has been studied in
PDAC for a while now but its role in PDAC remains largely unknown. CD109 expression
seems to be significantly higher in higher grade glioma, breast ductal carcinoma, nonsmall cell lung carcinoma, hepatocellular carcinoma, and soft tissue sarcomas, with the
exception of urothelial carcinoma where higher expression of CD109 corresponds to
lower grade disease [15-37]. Notably, CD109 is conserved across species, and is rarely
found mutated in cancer according to TCGA data.

PDAC cells
with weak CD109

PDAC cells
with moderate CD109

PDAC cells
Normal Duct
with 1.2:
strong
CD109
(negative)
Figure
CD109
is significantly
overexpressed in PDAC compared to normal
pancreas tissue
IHC scores are calculated according to the staining intensity as well as the percentage
of cells that stain positive for CD109 as determined by a pathologist (Figure adapted
from Huan R. et al 2014).
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1.6 CD109 Mechanism of Action
Aside from all that is unknown about CD109, there seems to be significant conflict on its
pathways of action. Initially a study showed CD109 downregulating TGF-β in
keratinocytes in vitro, however the CD109-/- mouse didn’t show significant difference in
smad2 phosphorylation, and instead stat3 phosphorylation increased [11, 13, 38, 39]. A
few years later another group studying fibrosis and wound healing used transgenic mice
overexpressing CD109 in the epidermis and noticed that they have better wound
healing through TGF-β suppression [40-42]. A third group used CD109 deficient mice
found that they have reduced skin tumorigenesis also by antagonizing TGF-β[43]. On
the other hand, in lung adenocarcinoma a team using KP mice demonstrated lower lung
metastases in CD109 knockdown cells through the enhancement of JAK/STAT3
pathway [34]. These different findings suggest that the role of CD109 might be tissue
and context dependent.

7

1.7 Project Summary and Hypothesis
CD109 has been considerably studied both in physiological and pathological
implications. Its controversial findings and association of CD109 with cancer initiation
and/or progression has found fresh interest in the research community. My interest in
CD109 began from unbiased screening as well as the fact that it is overexpressed in
pancreatic adenocarcinoma but its role in PDAC is virtually unstudied and unknown.
Based on our screen data, we hypothesized that CD109 expression is significantly
increasing PDAC cells survival. We wanted to first investigate the phenotype of CD109
deficiency in PDAC both in vitro and in vivo, to evaluate its tumor initiation property and
that the underlying molecular mechanisms are consistent with what was previously
mentioned in the literature.
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2. Materials and Methods
2.1 Cell Lines
PDAC models used are four human cell lines of early passaged xenografts derived from
PDAC patients in MD Anderson. The four models are PATC124 (Pancreatic
Adenocarcinoma Tumor Cell line), PATC69, PATC53, and PATC153. PATC53 is from a
liver metastasis, and the rest are from the primary tumor. PATC53 and PATC153 are
more mesenchymal like, while PATC124 and PATC69 are quasi-mesenchymal.
PATC124, PATC69 and PATC153 were maintained using DME/F12 growth medium
(HyClone) while PATC53 was maintained under Dulbecco's Modified Eagle's Medium
(DMEM) (HyClone). Growth media was supplemented with 10% Fetal Bovine Serum
(heat inactivated) (FBS-HI) (Gibco) and 1% Penicillin-Streptomycin (Pen-Strep) (Gibco).
Cell lines were subcultured when they reach 80%-90% confluency, and growth media
changed twice a week.
Cas9 cell lines of PATC124, 69, 53, and 153 were established and kept under similar
conditions to their parent cell line in addition to 1:100 blasticidin to select for the cas9
population.
Two hTERT HPNE cell lines, P52, and P51which are human pancreatic ductal cell lines
were maintained under complete growth medium recommended by the ATCC website
as follows:
•

75% DMEM without glucose (with additional 2 mM L-glutamine and 1.5 g/L
sodium bicarbonate)

•

25% Medium M3 Base
9

•

To make the complete growth medium, add the following components to the
base medium:

•

fetal bovine serum 5% (final conc.)

•

10 ng/ml human recombinant EGF

•

5.5 mM D-glucose (1g/L)

•

750 ng/ml puromycin

293T (ATCC® CRL-3216™) human embryonic kidney cell line was used for the
purpose of lentiviral production and maintained under complete growth medium DMEM
supplemented with 10% FBS-HI and 1% Pen-Strep. Cells are subcultured at about 6070% confluency and media changed twice a week.
The subculturing technique used for all cell lines is as follows:
•

Remove and discard culture medium.

•

Briefly rinse the cell layer with Dulbecco's phosphate-buffered saline (D-PBS).

•

Add 0.25% Trypsin-EDTA solution and observe cells until cell layer is dispersed.

•

Add complete growth medium and aspirate cells by gently pipetting.

•

Transfer cell suspension to a centrifuge tube and spin at approximately 1100 rpm
for 4 minutes. Discard supernatant.

•

Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of
the cell suspension to new culture vessels.

•

Incubate cultures at 37°C.
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2.2 Plasmid Production
pLKO.1 vectors encoding the short hairpin RNAs (shRNAs) targeting CD109 mRNA
(shCD109-1, shCD109-2, shCD109-3, shCD109-4), shRNA targeting Luciferase as a
negative control (shLuc-1), as well as single guide RNAs (sgRNAs) against CD109
gene (sgCD109-1, sgCD109-2), and sgRNAs against Luciferase as a negative control
(sgNC-1) were designed and produced by IACS facilities. Plasmids carry ampicillin
resistance gene.
Plasmids were used to transform NEB® 5-alpha Competent E. coli (High Efficiency)
according to the High Efficiency Transformation Protocol (C2987H/C2987I). After
transformation colonies are selected on 1:1000 Ampicillin LB plates. Two different
colonies are picked and incubated in 50 ml LB with 1:1000 ampicillin for 12-14 hours at
37°C under rotation. Plasmids are then collected using the QIAGEN Plasmid Plus Midi
Kit and according to the protocol, quantified using the NanoDropTM (Thermofisher), and
finally stored in -20°C.
2.3 Lentivirus Production
We used a lentivirus delivery system to introduce shRNAs for CD109 gene knockdown.
293T cells were co-transfected with the pLKO.1 vector encoding the shRNA and the
helper plasmids for virus production (psPAX2and pMGD2) using Lipofectamine 3000
according to the Lipofectamine 3000 protocol by Invitrogen.
Lentivirus was collected 72 hr after transfection and is then either spun down in the
ultracentrifuge resuspended in 100 ul PBS, and stored at -80°C or aliquoted, stored at
4°C and used within one week.
11

The lentiviral backbone has puromycin resistance gene and the PATC cell lines were
titrated against a range of puromycin concentrations to determine the optimum selection
concentration which was 1:5000. The cells were also titrated against the lentivirus to
optimize virus concentration used for transduction. Lentivirus infection was performed
using 1:1000 polybrene and after 24 hours cells were washed and selected in medium
with 1:5000 puromycin.
2.4 Rescue Model
We established a CD109 overexpressing line in PATC153 which originally has relatively
low endogenous CD109 expression. We transduced PATC153 with a gateway adapted
entry vector containing resistant CD109 ORF (referred to here as pHAGE CD109m).
The ORF is resistant to one of the hairpins (shCD109-3) and was developed by sitedirected mutagenesis (PCR-based strategy), and multiple synonymous mutations
across the binding site were included to reduce the binding efficiency of the shRNA. The
gateway is based on the pHAGE Gateway system. A separate PATC153 is transfected
with pHAGE-GFP as a control for the transduction process.
2.5 Inducible system
We attempted to produce conditional cell lines using a doxycycline inducible RNAi one
vector system pGLTR-X (Addgene) targeting CD109. It was a tetracycline on system
(rtTA). A multitude of doxycycline concentrations from 1:1000 to 1:100, and sampling
timepoints from 24 hr to 144 hours after the addition of doxycycline were tested,
however the results were less than satisfactory. Inducible CD109 knockdown was not
observed at all with ishCD109-2 construct and minimally achieved with ishCD109-3
after 72 hours post doxycycline. The cells were seeded under doxycycline for colony
12

formation and viability assays, compared to cells seeded without doxycycline and there
was no significant difference. We finally resorted to the constitutional knockdown
system.
2.6 Western Blot
Proteins were extracted from collected cell pellets in the presence of protease and
phosphatase inhibitors, and quantified using the Bradford method. Western blot analysis
was then performed using the standard protocols.
We used 20 ug protein for loading, run the gel at 90 v, and used wet transfer with
nitrocellulose membrane. After the transfer the membrane was then blocked in 5% milk
suspended in 1% TBST for one hour at least.
Primary antibody is anti CD109 mouse monoclonal antibody (1:100 in 5% milk TBST),
incubated with the membrane at 4°C overnight, then washed with 1% TBST three times
before incubating with LICOR secondary antibody mouse 800 nm (1:10000 in Odyssey
buffer). After three more washings with 1% TBST the membrane is scanned with
LICOR.
2.7 Colony Formation Assay
Cell lines were transduced with each of the CD109 shRNAs as well as the Luciferase
shRNA, and left to select under puromycin until the puromycin control plate is wiped.
After selection cells are collected and counted with the hemocytometer. For each
condition in triplicates 1500 cells are seeded per well in a 6 well plate, and left to form
colonies for 3 weeks. Colonies are then fixed with 6.0% v/v paraformaldehyde, stained
with 0.5% w/v crystal violet and visually compared and/or counted for quantification.
13

2.8 Cell Cycle Analysis
After selection PATC cells were incubated with BrdU and cell cycle assay was
performed as described in the cell cycle analysis protocol using the BD PharmingenTM
BrdU Flow Kit. Cell cycle analysis was performed by the South Campus Flow Cytometry
Facility. For each measurement at least 10000 events were captured. Data analysis
was performed using Flowjo software program.
2.9 Apoptosis Assay
After selection we followed the FITC Annexin V and Propidium Iodide Apoptosis
Detection Kit I protocol described by BD PharmingenTM. Uninfected sample was
exposed to heat shock as a positive control for apoptosis, and untreated sample as a
negative control for apoptosis.
2.10 Viability Assay
After selection cells from each condition were collected and counted. 2000 cells times
five replicates per condition were seeded in 96 well plate and the CellTiter-Glo®
Luminescent Cell Viability Assay protocol was followed.
2.11 Migration Assay
After selection PATC124 cells were starved for 24 hours in serum free DME/F-12
medium, harvested using 0.05% Trypsin and proceeded as described in QCMTM 24Well Colorimetric Cell Migration Assay protocol. We compared the migration observed
with untreated PATC124 and the negative control against the CD109 knockdown
conditions in the presence and absence of serum in the bottom chamber.
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2.12 Staining for CD109 at the Cell Surface
We followed the Flow Cytometry Protocol for Staining Membrane-associated Proteins in
Suspended Cells described by R&D Systems. We used human PE-conjugated antiCD109 by R&D for staining and performed a titration experiment to optimize antibody
concentration and ensure we capture all CD109 signal available.
2.13 In Vivo Tumorigenesis Assay
This assay was performed on PATC124. Cells were transduced with either shCD109-2,
shCD109-3, or shLuc-1. After selection cells were collected and counted. One million
cells times five replicates of each condition was resuspended in 100 ul PBS plus 100 ul
matrigel and injected subcutaneously in 14-weeks old female nude mice that were
randomly assigned into three experimental groups of five mice each. We followed up
the formation of tumors in each condition as well as the size and survival over a period
of 8 weeks. Animal experiments were performed at MD Anderson Cancer Center
Animal Facility and followed approved Institutional Animal Care and Use Committee
protocol 884-RN02.
2.14 Functional Proteomics by Reverse Phase Protein Assay (RPPA)
To compare CD109 overexpression against endogenous CD109 we transduced
PATC153 pHAGE-GFP and PATC153 pHAGE-CD109m with the two working CD109
working hairpins as well as the negative control hairpin. After selection three biological
replicates of each condition were collected and pelleted over a timecourse (48, 96, and
144 hr). Pellets were stored in -80°C until sample submission to the MD Anderson
RPPA Core Fcaility.
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Statistical analysis of the normalized log2 intensities was conducted with the Limma
package in R using the lmFit and eBayes function.
Hairpins shCD109-3 for pHAGE-CD109m vs pHAGE-GFP were compared and
differential proteins with p < 0.01 are reported (rescue protein expression in the context
of shCD109-3)
2.15 RNA Sequencing
We stained three biological replicates of untreated PATC124 cells for CD109 at the
surface and sorted CD109 negative and CD109 positive populations using FACS. RNA
from each sorted sample was extracted using the QIAGEN RNeasy Midi Kit and
following described kit protocol. After elution RNA content was calculated using
Nanodrop. Samples were submitted for Sanger sequencing at the MD Anderson
Sequencing and Microarray Facility (SMF).
Cd109 positive and negative populations were analyzed with DESeq using raw counts.
Significantly deregulated genes were identified using an adjusted p value of 0.05 and an
absolute log2foldchange greater than 1. GSEA preranked test was run on the t scores
obtained from the DESeq analysis.
2.16 Quantification and Statistical Analysis
P value was calculated in Microsoft Excel using a two-tailed Student t test. Cell culture
experiments were done with an n ≥ 3. In vivo studies have been performed using n = 5
mice/condition. Error bars in graphs represent the mean ± SD.
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Table 2.1 Antibodies
Name

Company

CD109

(C-9)

Notes

mouse

monoclonal antibody

Used for western blotting in
Santa Cruz Biotechnology

1:100 concentration.

Santa Cruz

1:10000

β-Actin mouse monoclonal
antibody

Used

for

surface
Human PE-conjugated antiCD109

for

surface
APC-conjugated

Mouse IgG2A Control PE

isotype

control

and

for

control

for

PE-

per 250000 cells)

kappa

conjugated

CD133

cell

conjugated CD109. (5 ul
R&D

IgG2b

staining

250000 cells)
IgG

Mouse

for

FACS analysis. (5 ul per
R&D

Conjugated

and

(5 ul per 250000 cells)
Used

anti-CD133

CD109

cell

FACS analysis and sorting.
R&D

Human

staining

IgG

APC

control

for

APC-

conjugated CD133. (5 ul
Invitrogen

per 250000 cells)
Fc Block (5 ul per 1 Million

Human TruStain FcXTM

Biolegend

cells)
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Table 2.2 Important Reagents and Kits
Name

Company

Lipofectamine 3000

Invitrogen

Accutase

Stem Cell Technologies

Medium M3 Base

Incell Corp
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3 Results
3.1 CD109 is a Common Vulnerability Among the PDAC Models
Loss of function genomic screens are an unbiased method of target discovery. Results
from our in vitro and in vivo loss of function screens performed on four different patient
derived PDAC cell populations show that CD109 is one of only five hits/vulnerabilities
that were common between the eight screens. Interestingly it scores alongside ERBB2,
ERBB3 (HER/EGFR family) which drive tumor growth in a significant percentage of
pancreatic cancers [44] (figure3.1)
The first thing we noticed from the screens is the differential vulnerability of CD109
across the four models (figure3.1). We wanted to see if the degree of vulnerability
correlates with the amount of CD109 protein in each model but it doesn’t quite align as
seen from western blot (figure3.1).
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Figure 3.1 Results from LOF screens on PATC124, PATC 69, PATC 53, and
PATC153 in vitro and in vivo
(a) Representation of the in vivo and in vitro results for each model as an RSA score.
Genes that score within the horizontal rectangle area are a vulnerability in vivo, and the
genes scoring within the vertical rectangle are a vulnerability in vitro. The circle
represents CD109 position in each plot.
(b) and (c) Table and Vinn diagram representation of the common hits between models
(d) Western blot showing different levels of CD109 expression between the four PDAC
models.
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3.2 CD109 influence on PDAC cell proliferation in Vitro
Clonogenic assays indicate the ability of a cell to divide and produce a colony in vitro.
We assayed colony formation in all four models using 3 different working hairpins
against CD109 and comparing to the negative control hairpin. Knockdown was
assessed using western blot, which shows that shCD109-2, and shCD109-3 hairpins
are much more efficient at eliminating CD109 than shCD109-4. All four models show
reduction in colony formation capacity that correlates to the level of knockdown of
CD109 (figure 3.2). Based on these results I focused on PATC124 since it had the
highest expression levels of CD109 and is the most vulnerable to its depletion. On the
other hand PATC153 exhibits the lowest expressing and least dependency on CD109. I
also excluded shCD109-4 because of its inefficient CD109 knockdown and only used
shCD109-2 (most efficient CD109 knockdown), and shCD109-3 (second most efficient)
besides the negative control hairpin shLuc-1. The shCD109-4 hairpin mainly served as
proof of correlation of phenotype to the level of CD109 knockdown.
We used PATC153 pHAGE-CD109m line which expresses a mutant form of CD109
resistant to shCD109-3 and compared its colony formation phenotype against PATC153
pHAGE-GFP control. This approach showed a partial rescue of phenotype that was
statistically significant (figure 3.3 and 3.4).
Next I wanted to further assess cell ability to proliferate in the absence of CD109, this
time using viability assay. I used CellTiter-Glo® which is a luminogenic ATP assay and
again CD109 deficient cells are less viable, the phenotype is less pronounced in
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PATC153 than PATC124, and is rescued in the PATC153 pHAGE-CD109m line (figure
3.5).
Having validated that there is a proliferation phenotype attributed to CD109 in our PDAC
models, we proceeded to evaluate cell cycle progression and apoptosis in PATC124
and PATC153. Both models seem to stall in G1 phase of the cell cycle in the CD109
knockdown conditions, but I observed no difference in the rate of apoptosis (figure 3.6).
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Figure 3.2 Colony Formation Assay
Scan of 6-well plates showing the effect of CD109 depletion on each of PATC124,
PATC69, PATC153, and PATC53 using 3 different shRNAs against CD109 gene, along
with western blot demonstrating the level of knockdown.
(a) PATC124 colony formation assay results.
(b) Western blot evaluating CD109 knockdown in PATC124 using the 3 hairpins and
control.
(c) PATC69 colony formation assay results.
(d) Western blot evaluating CD109 knockdown in PATC69 using the 3 hairpins and
control.
(e) PATC153 colony formation assay results.
(f) Western blot evaluating CD109 knockdown in PATC153 using the 3 hairpins and
control.
(g) PATC53 colony formation assay results.
(h) Western blot evaluating CD109 knockdown in PATC53 using the 3 hairpins and
control.
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Figure 3.3 Mutant CD109 is resistant to shCD109-3 knockdown
PATC153 pHAGE-CD109m is a CD109 overexpressing line which expresses a
resistant ORF to shCD109-3 due to multiple synonymous mutations across the binding
site.
The western blot confirms overexpression and resistance to shCD109-3. PATC153
pHAGE-GFP is a control for the transduction process.
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Figure 3.4 Colony Formation Partial Phenotype Rescue in PATC153
(a) A scan of the wells shows partial rescue of the colony formation phenotype
observed with shCD109-3.
(b) Colonies were counted for both PATC153 pHAGE-CD109m shCD109-3
knockdown wells (C3 Cm) and PATC153 pHAGE-GFP shCD109-3 wells (C3
GFP). Statistically significant difference using paired t test (p=0.001).
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Figure 3.5 Viability Assay Phenotype and Rescue
(a) Bar charts representing the relative viability as a percentage of untreated (non
infected) condition in PATC124 and PATC153.
(b) Viability phenotype rescue in PATC153 pHAGE-CD109m.
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Figure 3.6 Cell Cycle Analysis and Apoptosis in PATC124 and PATC153
CD109 knockdown in PATC124 and PATC153 results in stalling in the G1 phase of the
cell cycle, and doesn’t affect apoptosis in vitro.
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3.3 No effect on Migration in Vitro
CD109 in glioma seems to promote invasion and metastasis. To test this idea in our
models I performed a migration in vitro experiment using trans-well technique an, but
we didn’t observe any significant difference (Figure 3.7).
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Figure 3.7 Migration Assay in PATC124 and PATC153
No significant difference
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C3

3.4 In Vivo Phenotype Tumor Initiation Potential
Now it was evident CD109 deficiency reduces PDAC cell viability in vitro by stalling cell
cycle in the G1 phase, rather than direct induction of cell death. Sometimes an in vitro
phenotype doesn’t hold true in vivo which is why it was important to see if the absence
of CD109 significantly interferes with PDAC tumor formation and growth. We attempted
an inducible CD109 knockdown system and tested it in vitro in PATC124, but it didn’t
result in sufficient knockdown of CD109 to produce phenotype (figure 3.8 (a) and (b)).
We used the constitutive CD109 knockdown to inject nude mice randomly assigned to
shLuc-1, shCD109-2, or shCD109-3 groups. Each group consisted of 5 mice and we
observed that four out of five mice in the negative control developed tumors by week 5,
and all four reached ≥100 mm3 tumors and were euthanized by week 8. In the
shCD109-2 group none of the mice formed tumors, and in shCD109-3 three out of five
mice developed tumors, but only one of them reached the 100 mm3 threshold and was
euthanized (figure 3.8 (c)).
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Figure 3.8 In Vivo Tumorigenesis
(a) Western blot showing PATC124 inducible CD109 knockdown compared to
constitutive CD109 knockdown at 72 and 120 hr. (b) colony formation assay using
inducible CD109 system in PATC124. (c) Kaplan-Meier plot showing the survival
rate of mice after being injected with either PATC124 shLUC-1 cells, shCD109-2
cells, or shCD109-3 cells.
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3.5 CD109 is Differentially Expressed on the Cell Surface
In glioma CD109 was shown to mark a subset of cancer stem-like cells that were
separate from CD133 cancer stem-like cells. To check these results in PDAC I stained
all four models PATC124, PATC69, PATC53, and PATC153 cells for both CD109 and
CD133 and analyzed them by flow cytometry. Interestingly not all the cells within each
model were expressing cell surface CD109 and CD133 but it seemed there were two
separate subpopulations expressing either one. Also the percentage of CD109 positive
cells in the four models corresponded to the level of expression of that model, where
PATC124 has almost 60% CD109 positive cells, and PATC153 has less than 3%
CD109 positive cells (figure 3.10). We sorted CD109 positive and CD109 negative cells
to check protein levels using western blot and the CD109 positive population has much
higher CD109 content as expected, but at the same time CD109 negative cells still
showed a faint band of CD109 protein, knowing that the ratio of antibody to number of
cells has been titrated and so this is not due to an under saturation of the cells with the
antibody (figure 3.9). We sorted and recultured CD109 positive and CD109 negative
cells separately for eight days which corresponds to eight cell doubling times, then
reanalyzed the percentage of CD109 positive and negative in each. As seen in figure
3.10 (d) both populations come back to the original CD109 positive to negative ratio.
The finding that we have about 40% of CD109 negative population in PATC124 and still
demonstrate such a profound cell proliferation phenotype suggests that either CD109
positive cells have a direct influence on the surrounding cells or that CD109 is being
expressed internally in CD109 negative cells and still playing a role in regulating cell
proliferation. In order to rule out the possibility of off-target effects from the two working
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hairpins I checked CD109 expression in normal pancreatic cell lines hTERT HPNE P52
and P51. As seen from figure 3.11 there is almost no CD109 expression detected with
these lines, so we transduced HPNE 52 with shLuc-1, shCD109-2, and shCD109-3, and
seeded them to evaluate colony formation which showed no significant difference.
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Figure 3.9 Titration of CD109 PE conjugated antibody against the number of cells
The amount of antibody used is kept constant, and used to stain 500000, 250000, or
125000 cells. Saturation is achieved at 250000 cells.
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Figure 3.10 Distribution of CD109 and CD133 positive cells in the four models
(a) FACS analysis of each model according to CD109 and CD133 staining. Green =
Untreated, Red = CD109 + CD133, Blue = IgG2A (CD109 antibody control),
Orange = IgGB2 (CD133 antibody control )
(b) Western blot showing PATC124 CD109 positive against CD109 negative cells.
(c) Western blot of CD109 levels in each model.
(d) FACS analysis of sorted CD109 positive and CD109 negative cells after four
doublings.
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Figure 3.11 CD109 knockdown in HPNE
(a) Colony formation assay in HPNE P52 shows no difference when treated with
shCD109-2, shCD109-3, than with shLuc-1.
(b) Western blot detecting CD109 in PATC124 and not in HPNE P52, or P51.
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3.6 CD109 Mechanism of Action Involves Some Known Interactors
We used reverse phase protein lysate array (RPPA) to compare the signaling between
knockdown and rescue of CD109 in PATC153 overexpressing line p HAGE-CD109m
and the control PATC153 pHAGE-GFP. The top scoring proteins which were enriched
in the CD109 overexpressing condition included pYAP, total YAP, pRb, pHER3, and
others as seen in the table from figure 3.12.
We also looked into differential mRNA expression between freshly sorted CD109
positive and CD109 negative cells from three different PATC124 samples(figure 3.13
(a)). CD109 levels were confirmed by western blot. RNA sequencing data is still under
further analysis and validation but we were able to detect enrichment of YAP signature
in the CD109 positive group.
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Figure 3.12 RPPA Knockdown –PATC153 (GFP/CD109m)
(a) Table arranging the top scoring proteins from the RPPA results in order of highest fold change.
(b) Western blot confirming CD109 knockdown in submitted samples.
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Figure 3.13 RNA Sequencing Analysis of PATC124 CD109 positive and CD109
negative cell populations
(a) Flow cytometry sorting data showing the chosen separation between CD109
positive and negative signals in three different samples.
(b) Western blot of the sorted populations.
(c) Volcano plot visualization of RNASeq results.
(d) Enrichment plots of some of the captured signaling.
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4. Discussion and Future Directions
4.1 Discussion
Pancreatic adenocarcinoma is considered the most fatal common cancer nowadays.
PDAC is mostly diagnosed at an advanced stage when the disease has already
metastasized and surgical resection is no longer an effective option. It is largely
resistant to chemotherapy and has remained within the same 8% 5-year survival rate for
decades now despite nonstop research efforts. In this study I investigate CD109 cell
surface protein based on our preliminary data from loss of function LOF RNAi screen
findings on PDAC models. CD109 has been implicated in various types of cancers but it
had not been studied in the context of PDAC yet. I focused on validating and specifying
a phenotype of CD109 deficiency in PDAC cells in vitro using an shRNA CD109
knockdown system. Our results show significant reduction in colony formation capacity
and viability across the four PDAC models in the absence of CD109 expression, a
reduction that corresponded to the actual level of CD109 knockdown. A partial rescue of
both the colony formation phenotype and the viability phenotype further support this
observation. To further validate the specificity of the phenotype to CD109 we
transduced a normal pancreatic ductal cell line hTERT HPNE P52 which doesn’t
express CD109 protein with our set of CD109 targeting hairpins shCD109-2, and
shCD109-3, and shLuc-1 as a negative control. When we assayed the cells for colony
formation we couldn’t detect any significant difference. Together this data suggests that
CD109 is influencing the survival of PDAC cells in our models.
Next, we questioned whether this reduction is a result of induced cell death or not, so
we evaluated cell cycle progression, and the rate of apoptosis in the CD109 knockdown
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condition compared to the negative control. Cell cycle appeared to be stalling in the G1
phase, while there seems to be no effect on apoptosis. This means that CD109 is not
directly causing cells to die, and might be supporting the TGF-β pathway theory.
Previous studies on glioma and lung cancer have shown that CD109 is pro-metastatic.
We tested this in our PDAC models in vitro using migration assays and we couldn’t
capture a significant difference on that front. This pro-metastatic property might not be
significant in PDAC [24, 34, 36, 37].
A recent study in glioma has also revealed that CD109 is marking a certain population
of cancer stem like cells which is mutually exclusive with CD133 positive cancer stem
like cells[37]. We wanted to check if this applies to our models and found that there is a
specific percentage of CD109 expressing cells in each PDAC model, that correlates to
the amount of CD109 protein detected on western blot, but when we sorted the CD109
negative populations and ran them on western blot we were able to detect a small level
of CD109 protein present. So even though CD109 is not detected on the surface of
these cells it is still minimally expressed. This might explain why we didn’t see this
CD109 negative population in our previous assays. We decided to sort the positive and
negative populations of the highest CD109 expressing line PATC124 and reculture
them separately. After about four doubling times, both CD109+ and CD109- populations
eventually produce almost the same ratio of CD109+ to CD109- as their parent line.
This means that CD109 protein is not exclusively present at the surface of PDAC, but
can also be found in the cytoplasm of the cells, and in this case cells that are negatively
staining for cell surface CD109 are still capable of CD109 expression and might have
intracellular CD109 that is functionally active. It also implies the presence of a critical
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homeostasis of CD109 expression allowing PDAC cells to control the amount and
percentage of CD109. This is in contrast to what was published recently about the
higher hierarchy of CD109+ cells in glioma and the inability of CD109- cells to give rise
to CD109+, while the opposite is possible [37].
We have also attempted an in vivo validation of the phenotype, by injecting nude mice
with either CD109 knockdown cells or the negative control and noticed that none of the
mice injected with shCD109-2 knockdown cells formed tumors, compared to 80% of the
negative control group. This experiment is still ongoing in order to determine survival
differences between the two groups and to obtain IHC data.
Finally we wanted to investigate the interactors and pathways CD109 might be acting
through in PDAC. There has been conflicting data on this aspect in the literature,
suggesting that signaling downstream of CD109 are probably context and/or site
dependent. We performed two different experiments to answer this question, first was to
look at the differential signaling between knockdown and rescue of CD109 protein
through RPPA which detects differences in protein expression. Our data notably show
significant changes in YAP and pYAP. CD109 involvement in the YAP/TAZ pathway in
glioma has also been recently reported, and supports the tumor initiation property of
CD109.
The second experiment was to sort CD109 positive and CD109 negative cells and
compare their differential mRNA expression, which this time was able to capture TGF-β
enrichment as well as YAP and pRb.
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4.2 Future Directions
Although we were able to validate the pro-oncogenic effect of CD109 expression in
PDAC cells, and show an insight into possible downstream signaling, further work
needs to be done and is actually ongoing to specify CD109 interactors in PDAC. We
have successfully established a flag tagged CD109 that is expressed on the surface
and we are currently in the process of doing a pilot Co-Immunoprecipitation/MS
experiment to get a more solid idea on what proteins are directly binding to CD109.
We also want to test the translational significance of CD109 as a therapeutic target.
Less than a year ago, a group reported failure of CD109 to internalize following
monoclonal antibody binding[16]. We noticed, however, the association of CD109 with
HER-3 in our RPPA data as well as data from the screens. There is an exciting
possibility that designing a bi-functional antibody targeting both CD109 and a relevant
cell surface receptor such as HER-3 could enhance the internalization of both and
consequently reduce PDAC cell survival.
Finally, the role of CD109 as a secreted protein as well as a cell surface marker is too
important to ignore, especially in the case of PDAC. Further investigations are
warranted to provide insight on the timing and stage at which CD109 is detectable or
overexpressed in PDAC as well as in other CD109 overexpressing tumors and the
potential of CD109 as a new biomarker for these tumors.
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